Galapagos Exploring Divesting From Cell Therapy Business

Dow Jones10-02

By Katherine Hamilton

Galapagos is exploring strategic alternatives for its cell therapy business, including a potential divestiture.

The Belgian biotechnology company said Wednesday it has received a limited number of non-binding offers, mostly from financial investors, to acquire the cell therapy business. Parties interested in acquiring the business have had access to a comprehensive data room and confidential presentations on the cell therapy business.

Galapagos' board and management are now working with the potential bidders to finalize due diligence and see if they can raise the necessary funding. The deadline for potential bidders to put forward fully financed binding offers will happen in the coming weeks, Galapagos said.

The board expects to make a decision about which strategic alternative it will choose after it receives those binding offers, if there are any. Galapagos will announce its decision no later than Nov. 5, when it plans to release its third-quarter results, it said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

October 01, 2025 16:27 ET (20:27 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2572557466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 04:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572557466","market":"hk","top_or_hot":-1,"title":"Galapagos Exploring Divesting From Cell Therapy Business","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Galapagos is exploring strategic alternatives for its cell therapy business, including a potential divestiture. \n</p>\n<p>\n  The Belgian biotechnology company said Wednesday it has received a limited number of non-binding offers, mostly from financial investors, to acquire the cell therapy business. Parties interested in acquiring the business have had access to a comprehensive data room and confidential presentations on the cell therapy business. \n</p>\n<p>\n  Galapagos' board and management are now working with the potential bidders to finalize due diligence and see if they can raise the necessary funding. The deadline for potential bidders to put forward fully financed binding offers will happen in the coming weeks, Galapagos said. \n</p>\n<p>\n  The board expects to make a decision about which strategic alternative it will choose after it receives those binding offers, if there are any. Galapagos will announce its decision no later than Nov. 5, when it plans to release its third-quarter results, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 01, 2025 16:27 ET (20:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galapagos Exploring Divesting From Cell Therapy Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalapagos Exploring Divesting From Cell Therapy Business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-02 04:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Galapagos is exploring strategic alternatives for its cell therapy business, including a potential divestiture. \n</p>\n<p>\n  The Belgian biotechnology company said Wednesday it has received a limited number of non-binding offers, mostly from financial investors, to acquire the cell therapy business. Parties interested in acquiring the business have had access to a comprehensive data room and confidential presentations on the cell therapy business. \n</p>\n<p>\n  Galapagos' board and management are now working with the potential bidders to finalize due diligence and see if they can raise the necessary funding. The deadline for potential bidders to put forward fully financed binding offers will happen in the coming weeks, Galapagos said. \n</p>\n<p>\n  The board expects to make a decision about which strategic alternative it will choose after it receives those binding offers, if there are any. Galapagos will announce its decision no later than Nov. 5, when it plans to release its third-quarter results, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 01, 2025 16:27 ET (20:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572557466","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572557466","pubTimestamp":1759350420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Galapagos is exploring strategic alternatives for its cell therapy business, including a potential divestiture.The Belgian biotechnology company said Wednesday it has received a limited number of non-binding offers, mostly from financial investors, to acquire the cell therapy business. Parties interested in acquiring the business have had access to a comprehensive data room and confidential presentations on the cell therapy business.Galapagos' board and management are now working with the potential bidders to finalize due diligence and see if they can raise the necessary funding. The deadline for potential bidders to put forward fully financed binding offers will happen in the coming weeks, Galapagos said.The board expects to make a decision about which strategic alternative it will choose after it receives those binding offers, if there are any. Galapagos will announce its decision no later than Nov. 5, when it plans to release its third-quarter results, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLPG":"Galapagos NV"},"translate_title":"加拉帕戈斯探索剥离细胞治疗业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLPG":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Galapagos is exploring strategic alternatives for its cell therapy business, including a potential divestiture. \n\n\n  The Belgian biotechnology company said Wednesday it has received a limited number of non-binding offers, mostly from financial investors, to acquire the cell therapy business. Parties interested in acquiring the business have had access to a comprehensive data room and confidential presentations on the cell therapy business. \n\n\n  Galapagos' board and management are now working with the potential bidders to finalize due diligence and see if they can raise the necessary funding. The deadline for potential bidders to put forward fully financed binding offers will happen in the coming weeks, Galapagos said. \n\n\n  The board expects to make a decision about which strategic alternative it will choose after it receives those binding offers, if there are any. Galapagos will announce its decision no later than Nov. 5, when it plans to release its third-quarter results, it said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 01, 2025 16:27 ET (20:27 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2572557466","isCrawlerRequest":true}